Pye Hannah V, Krishnamurthi Revathy, Cook Ryan, Adriaenssens Evelien M
Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.
Centre for Microbial Interactions, Norwich Research Park, Norwich, NR4 7UG, UK.
Essays Biochem. 2024 Dec 17;68(5):607-619. doi: 10.1042/EBC20240012.
One Health aims to bring together human, animal, and environmental research to achieve optimal health for all. Bacteriophages (phages) are viruses that kill bacteria and their utilisation as biocontrol agents in the environment and as therapeutics for animal and human medicine will aid in the achievement of One Health objectives. Here, we assess the diversity of phages used in One Health in the last 5 years and place them in the context of global phage diversity. Our review shows that 98% of phages applied in One Health belong to the class Caudoviricetes, compared to 85% of sequenced phages belonging to this class. Only three RNA phages from the realm Riboviria have been used in environmental biocontrol and human therapy to date. This emphasises the lack in diversity of phages used commercially and for phage therapy, which may be due to biases in the methods used to both isolate phages and select them for applications. The future of phages as biocontrol agents and therapeutics will depend on the ability to isolate genetically novel dsDNA phages, as well as in improving efforts to isolate ssDNA and RNA phages, as their potential is currently undervalued. Phages have the potential to reduce the burden of antimicrobial resistance, however, we are underutilising the vast diversity of phages present in nature. More research into phage genomics and alternative culture methods is required to fully understand the complex relationships between phages, their hosts, and other organisms in the environment to achieve optimal health for all.
“同一健康”旨在整合人类、动物和环境研究,以实现所有人的最佳健康状态。噬菌体是一类能杀死细菌的病毒,其作为环境中的生物防治剂以及动物和人类医学的治疗手段,将有助于实现“同一健康”目标。在此,我们评估了过去5年用于“同一健康”的噬菌体的多样性,并将其置于全球噬菌体多样性的背景下。我们的综述表明,应用于“同一健康”的噬菌体中有98%属于有尾噬菌体目,而在已测序的噬菌体中,这一比例为85%。迄今为止,仅来自核糖病毒界的三种RNA噬菌体被用于环境生物防治和人类治疗。这凸显了商业用途和噬菌体治疗中使用的噬菌体在多样性上的不足,这可能是由于噬菌体分离方法和应用选择方法存在偏差所致。噬菌体作为生物防治剂和治疗手段的未来将取决于分离新基因双链DNA噬菌体的能力,以及加大单链DNA和RNA噬菌体的分离力度,因为它们的潜力目前被低估了。噬菌体有潜力减轻抗菌药物耐药性的负担,然而,我们对自然界中存在的大量噬菌体的利用还不够充分。需要对噬菌体基因组学和替代培养方法进行更多研究,以充分了解噬菌体与其宿主以及环境中其他生物之间的复杂关系,从而实现所有人的最佳健康状态。